Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Heterozygous FH Patients on Stable Lipid-Lowering Therapy Requiring Additional LDL-C Reduction

NCT04797104 is registered in ClinicalTrials.gov with LIB Therapeutics LLC as lead sponsor.

NCT NCT04797104
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04797104 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Heterozygous FH Patients on Stable Lipid-Lowering Therapy Requiring Additional LDL-C Reduction
Lead sponsor
LIB Therapeutics LLC
Phase
Phase 3
Overall status
Completed
Start date
April 22, 2021
Completion date
December 5, 2023
Enrollment
478 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

heterozygous familial hypercholesterolemia